Search results for "ALZHEIMER"

showing 10 items of 706 documents

IMMUNOLOGY OF AGING

2012

InflammationSettore MED/04 - Patologia GeneraleAgingImmune systemAlzheimerCentenarian
researchProduct

Synthesis and characterization of a new insulin conjugated nanogel for biomedical application

2015

Insulin, a metabolic hormone involved in glucose metabolism, plays also a neuroprotective role in the central nervous system being able to revert the cytotoxic processes induced by Aβ42,a peptide involved in Alzheimer's disease. To reach the brain insulin have to across the BBB therefore an additional delivery strategy results to be necessary. For these aim we performed an insulin conjugated nanogels (NGs-In). Nanogels (NGs) have a great potential in the development of “smart” nanocarriers for (bio)molecular drugs and contrast agent for bioimaging. They are formed by physically or chemically crosslinked polymer networks, characterized by a large and flexible surface available for multivalen…

Insulin nanogel Alzheimer's DiseaseSettore CHIM/07 - Fondamenti Chimici Delle Tecnologie
researchProduct

An intraoral drug delivery device for long term therapies: application in Alzheimer’s disease

2009

IntelliDrug intraoral device Alzheimer diseaseSettore CHIM/09 - Farmaceutico Tecnologico Applicativo
researchProduct

Plasticity Molecule Reveals Interneuronal Alterations in Alzheimer’s Disease

2017

InterneuronGeneral NeurosciencePsa ncamBrainNeural Cell Adhesion Molecule L1Human brainDiseaseBiologyPlasticityEntorhinal cortexmedicine.anatomical_structureAlzheimer DiseaseSialic AcidsmedicineEntorhinal CortexHumansNeuroscienceNeuroscience
researchProduct

A New Tool for the Analysis of the Effect of Intracerebrally Injected Anti-Amyloid-β Compounds

2021

Background: A wide range of techniques has been developed over the past decades to characterize amyloid-β (Aβ) pathology in mice. Until now, no method has been established to quantify spatial changes in Aβ plaque deposition due to targeted delivery of substances using ALZET® pumps. Objective: Development of a methodology to quantify the local distribution of Aβ plaques after intracerebral infusion of compounds. Methods: We have developed a toolbox to quantify Aβ plaques in relation to intracerebral injection channels using Zeiss AxioVision® and Microsoft Excel® software. For the proof of concept, intracerebral stereotactic surgery was performed in 50-day-old APP-transgenic mice injected wit…

Intracerebral injectionAmyloid βMice TransgenicPlaque Amyloidamyloid-βtransgenic miceStereotaxic TechniqueshistologyMiceAlzheimer DiseaseAnimalsHumansDistribution (pharmacology)implantable infusion pumpdistributional activityAmyloid beta-PeptidesChemistryGeneral NeuroscienceBrainGeneral MedicineImmunohistochemistryplaquesAβ depositionquantificationDisease Models AnimalPsychiatry and Mental healthClinical PsychologyGeriatrics and GerontologyAlzheimer’s diseaseResearch ArticleBiomedical engineeringJournal of Alzheimer's Disease
researchProduct

Effects of anti-inflammatory and adaptogenic herbal extracts on gene expression of eicosanoids signaling pathways in isolated brain cells.

2019

Abstract Introduction The adaptogens modulate expression of genes playing key roles in development of aging-related disorders, which are considered as low-grade systemic inflammatory conditions characterized by an imbalance between pro-and anti-inflammatory eicosanoids. Aim of the Study We compared the effects of anti-inflammatory and adaptogenic plant extracts on the expression of genes involved in biosynthesis of eicosanoids with the purpose to find those plants, which selectively upregulated the expression of anti-inflammatory lipoxins signaling pathways and inhibited pro-inflammatory signaling pathways associated with biosynthesis of leukotrienes, prostaglandins and thromboxanes. Materi…

Leukotrienesmedicine.medical_treatmentAnti-Inflammatory AgentsPharmaceutical ScienceEleutherococcusWithania somniferaPharmacologyWithania03 medical and health sciences0302 clinical medicineAlzheimer DiseaseDrug DiscoveryGene expressionAdaptogenmedicineHumans030304 developmental biologyPharmacology0303 health sciencesPlants MedicinalbiologyPlant ExtractsSequence Analysis RNAWithaniabiology.organism_classificationLeukotriene signaling pathwayRhodiola roseaComplementary and alternative medicineEicosanoidGene Expression Regulation030220 oncology & carcinogenesisMolecular MedicineEicosanoidsRhodiolaSignal transductionTranscriptomeNeurogliaSignal TransductionPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Accuracy of the clinical diagnosis of dementia with Lewy bodies (DLB) among the Italian Dementia Centers: a study by the Italian DLB study group (DLB…

2022

Introduction: Dementia with Lewy bodies (DLB) may represent a diagnostic challenge, since its clinical picture overlaps with other dementia. Two toolkits have been developed to aid the clinician to diagnose DLB: the Lewy Body Composite Risk Score (LBCRS) and the Assessment Toolkit for DLB (AT-DLB). We aim to evaluate the reliability of these two questionnaires, and their ability to enhance the interpretation of the international consensus diagnostic criteria. Methods: LBCRS and AT-DLB were distributed to 135 Italian Neurological Centers for Cognitive Decline and Dementia (CDCDs), with the indication to administer them to all patients with dementia referred within the subsequent 3 months. We…

Lewy Body DiseaseClinical diagnosiDementia with Lewy bodieConsensus criteriaDementia with Lewy bodiesDermatologybehavioral disciplines and activitiesDiagnostic accuracyDiagnosis DifferentialAlzheimer DiseaseDiagnosismental disordersHumansReproducibility of ResultsDiagnostic toolkitGeneral MedicineClinical diagnosis; Cognitive impairment; Consensus criteria; Dementia; Dementia with Lewy bodies; Diagnostic accuracy; Diagnostic toolkitsClinical diagnosisnervous system diseasesSettore MED/26 - NEUROLOGIAPsychiatry and Mental healthCognitive impairmentItalyDifferentialDiagnostic toolkitsDementiaNeurology (clinical)
researchProduct

Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: a meta-analysis of longitudinal studies.

2019

Objective: To synthesize the evidence across longitudinal studies comparing survival in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Methods: We conducted a systematic review and meta-analysis of studies comparing survival in clinically diagnosed DLB to AD. Longitudinal cohort studies were identified through a systematic search of major electronic databases from inception to May 2018. A random effects meta-analysis was performed to calculate survival time and relative risk of death. Results: Overall, 11 studies were identified including 22,952 patients with dementia: 2029 with DLB (mean diagnosis age 76.3; 47% female) compared with 20,923 with AD (mean diagnosis age 77.2; 6…

Lewy Body DiseaseMale0301 basic medicineAgingmedicine.medical_specialtyDiseaseBiochemistryLewy bodie03 medical and health sciences0302 clinical medicineA meta-analysis of longitudinal studies.- Ageing research reviews cilt.50 ss.72-80 2019 [MUELLER C. Soysal P. RONGVE A. ISIK A. THOMPSON T. MAGGI S. SMITH L. Basso C. STEWART R. BALLARD C. et al. -Survival time and differences between dementia with Lewy bodies and Alzheimer-s disease following diagnosis]Alzheimer DiseaseInternal medicinemental disordersmedicineHumansDementiaLongitudinal StudiesLongitudinal cohortMortalityMolecular BiologyAgedDementia with Lewy bodiesbusiness.industryCognitive scoreAlzheimer's diseaseRandom effects modelmedicine.diseaseSurvival RateObservational Studies as Topic030104 developmental biologyNeurologyMeta-analysisRelative riskFemaleDementiabusinessLewy bodiesAlzheimer’s disease030217 neurology & neurosurgeryBiotechnology
researchProduct

Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types.

2008

Objective:  i) to describe the neuropsychiatric profile of elderly subjects with dementia by comparing vascular (VaD) and degenerative dementias, i.e. dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD); ii) to assess whether the severity and type of dementia are associated with clinically relevant neuropsychiatric symptoms (CR-NPS). Method:  One hundred and thirty-one out-patients with VaD, 100 with DLB and 690 with AD were studied. NPS were evaluated by the neuropsychiatric inventory (NPI). Results:  Vascular dementia had lower total and domain-specific NPI scores and a lower frequency of CR-NPS than AD and DLB, for which frequency of CR-NPS increased significantly with disease s…

Lewy Body DiseaseMalemedicine.medical_specialtyPathologyPsychometricsDiseaseNeuropsychological TestsCentral nervous system diseaseDegenerative diseaseAlzheimer DiseaseInternal medicinemental disordersmedicineDementiaHumansVascular dementiaAgedAged 80 and overLewy bodyDementia with Lewy bodiesDementia Vasculartechnology industry and agricultureReproducibility of Resultsneuropsychiatric symptoms vascular dementia dementia with Lewy bodies Alzheimer’s disease dementia severitymedicine.diseasePsychiatry and Mental healthnervous systemDisease ProgressionSettore MED/26 - NeurologiaFemaleAlzheimer's diseasePsychologyActa psychiatrica Scandinavica
researchProduct

Analysis of the LRP10 gene in patients with Parkinson's disease and dementia with Lewy bodies from Southern Italy

2020

Recently, the LRP10 gene has been associated with Parkinson's disease (PD), Parkinson's disease with dementia (PDD), and dementia with Lewy bodies (DLB). The aim of the present study was to evaluate the presence of mutations of the LRP10 gene in patients with PD or DLB from Southern Italy. Sequencing analysis revealed only 2 missense and 3 synonymous variants in patients and control subjects and a rare variant p.L622F in a PD case. These results suggest that LRP10 mutations are not a frequent cause of PD and DLB in Southern Italy.

Lewy Body Diseasemedicine.medical_specialtyNeurologyParkinson's diseaseLRP10 . Parkinson’s disease . Dementia with Lewy bodiesDermatologyDiseasebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineDementia with Lewy bodies; LRP10; Parkinson's disease.mental disordersmedicineDementiaMissense mutationHumans030212 general & internal medicineNeuroradiologyDementia with Lewy bodiesbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasenervous system diseasesPsychiatry and Mental healthItalyMutationSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgery
researchProduct